For: | Yang J, Wang Y, Tong XM. Sintilimab-induced autoimmune diabetes: A case report and review of the literature. World J Clin Cases 2022; 10(4): 1263-1277 [PMID: 35211559 DOI: 10.12998/wjcc.v10.i4.1263] |
---|---|
URL: | https://www.wjgnet.com/2307-8960/full/v10/i4/1263.htm |
Number | Citing Articles |
1 |
Huijing Dong, Shengfu Li, Yanmei Peng, Xu Zhang, Jiabin Zheng, Chongxiang Xue, Yumin Zheng, Yixuan Yu, Xingyu Lu, Zixin Hu, Huijuan Cui. Durvalumab‑induced type 1 diabetes mellitus in lung adenocarcinoma: A case report and literature review. Oncology Letters 2025; 29(6): 1 doi: 10.3892/ol.2025.15023
|
2 |
Anmar Al-Taie, Najat Sheta. Clinically Approved Monoclonal Antibodies–based Immunotherapy: Association With Glycemic Control and Impact Role of Clinical Pharmacist for Cancer Patient Care. Clinical Therapeutics 2024; 46(1): e29 doi: 10.1016/j.clinthera.2023.10.016
|
3 |
Cuiping Lin, Xuan Li, Yu Qiu, Zheng Chen, Jianping Liu. PD-1 inhibitor-associated type 1 diabetes: A case report and systematic review. Frontiers in Public Health 2022; 10 doi: 10.3389/fpubh.2022.885001
|
4 |
|
5 |
Zijian Qiu, Mixue Sun, Chunyan Dai, Xiaoping Zhu. Immunotherapy-associated autoimmune hemolytic anemia induced by anti-PD-1 therapy in esophageal cancer: A case report and literature review. Medicine 2025; 104(15): e42174 doi: 10.1097/MD.0000000000042174
|